Navigation Links
Commercial Release of 3D (Breast Tomosynthesis) Biopsy Option Strengthens Hologic's Position as Provider of the Nation's Most Comprehensive Portfolio of Interventional Breast Health Solutions
Date:7/15/2013

BEDFORD, Mass., July 15, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, recently expanded its extensive array of interventional and imaging solutions for breast health with the launch of the world's first 3D breast biopsy option. This technology was developed for the Company's Affirm upright breast biopsy guidance system, which is used in conjunction with the Selenia Dimensions 2D and 3D mammography systems. 

The Affirm 3D biopsy procedure is designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions not always detected in 2D images or when using other modalities. This new biopsy technique has numerous advantages over traditional stereotactic biopsy procedures, including faster lesion targeting and reduced patient procedure time. In addition, the Affirm system is pre-programmed for use with the Company's Eviva and ATEC vacuum-assisted breast biopsy devices, providing easy integration of these best-in-class products.In June 2013, Magee-Womens Hospital of UPMC became the first facility in the nation to perform a tomosynthesis biopsy, a significant milestone for this new technology. Dr. Jules Sumkin, Chief of Radiology at Magee, performed the Affirm 3D biopsy procedure using the Eviva device. Additional information about this ground-breaking procedure can be found by following this link to the UPMC newsroom."The Affirm 3D biopsy option is an important addition to our product portfolio," says Dave Danielsen, Hologic's Vice President and General Manager, Breast Imaging. "Physicians now have a new tool, tomosynthesis, to accurately identify regions of interest for biopsy. This addresses an emergent need users of our 3D mammography systems have identified - a biopsy technology that helps them locate lesions seen only on tomosynthesis images, as well as lesions that are better visualized using 3D imaging."

The 3D biopsy option joins Hologic's comprehensive suite of interventional breast health products, allowing users to depend on a single vendor for the majority of their breast health clinical needs. In addition to the Affirm upright biopsy system, the Company's MultiCare Platinum biopsy table can be used to perform prone biopsy procedures. The versatile ATEC vacuum-assisted breast biopsy system can be used to perform biopsies under stereotactic, ultrasound, MRI or tomosynthesis guidance using the Company's Eviva or ATEC devices. Hologic also provides a full line of biopsy site markers for use in all breast biopsy modalities.

Specimen radiography needs, whether in the operating room or imaging suite, can be met with Hologic's Trident specimen radiography system. This system was developed in response to customer requests and utilizes Hologic's flagship amorphous selenium, direct-capture detector, ensuring high-quality specimen imaging.

About Hologic, Inc. Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women. The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health. With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives. The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.

Hologic, Affirm, ATEC, Dimensions, Eviva, MultiCare Platinum, Selenia and Trident are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward Looking Statement Disclaimer This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.ContactsMarianne  McMorrowPat HallGlobal PR and Advertising PublicistDirector of Corporate CommunicationsHologic, Inc.Hologic, Inc.Marianne.McMorrow@Hologic.com Pat.Hall@Hologic.com Tel: +1 781 999 7723Tel: +1 781 999 7463 


'/>"/>
SOURCE Hologic, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
2. Global Good and AUCMA Partner to Commercialize Vaccine Storage Invention for Developing Countries
3. Tom Dugan Joins SurgiQuest, Inc. as President and Chief Commercialization Officer
4. Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrxs Antibody Drug Conjugate for Breast Cancer
5. Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
6. Quantum Materials Tetrapod Quantum Dots Break Kashas Rule: Enhanced Performance Enables Commercialization of Novel Discovery
7. SI-BONE, Inc. annuncia la pubblicazione dei dati sulla sicurezza della sorveglianza post-commercializzazione per i primi 5.319 pazienti trattati con il sistema di impianto iFuse Implant System
8. Agendia Appoints Peter W. Schineller as Chief Commercial Officer
9. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
10. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
11. National Patient Advocate Foundations Annual Capitol Hill Briefing Focuses on Patient Access Barriers to Life-Saving Medicines Placed on Specialty Tiers by Commercial Insurance Plans and Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials ... combine to progress molecular radiotherapy imaging. In molecular ... to accurately quantify the radiation absorbed by those patients undergoing ... of this radiotherapy treatment has been available — that is, ... ...
Breaking Medicine Technology:
(Date:7/24/2017)... TX (PRWEB) , ... July 24, 2017 , ... ... student scholarship will be awarded for the fall semester to a deserving student. ... Emergency Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health ... Mental Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. ... Services, will facilitate the development of a hub and spoke model for opioid ...
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm fire in ... and threatened numerous homes and businesses nearby, causing some 700 individuals to be ... Angeles Area consulting firm Fire Protection Group, Inc. notes that the report is ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will ... essential tremor (ET). The seminar will take place on Saturday, Aug. 26 at the ... The program will run from 9 a.m. to 12 p.m., with check-in beginning at ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider ... partnered with WALLIX to expand its solution to help government contractors more ... a number of ways to address the authentication requirements within NIST SP800-171, but ...
Breaking Medicine News(10 mins):